share_log

Transcode Therapeutics | 424B5: Prospectus

Transcode Therapeutics | 424B5: Prospectus

Transcode Therapeutics | 424B5:募資說明書
美股SEC公告 ·  07/23 04:13

牛牛AI助理已提取核心訊息

TransCode Therapeutics, Inc. has announced the offering of common stock, pre-funded warrants to purchase common stock, and shares of common stock issuable upon the exercise of pre-funded warrants. The offering is detailed in a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. The prospectus supplement, dated July 22, 2024, outlines the terms of the offering, including the purchase price of shares and pre-funded warrants, the immediate exercisability of the pre-funded warrants, and the lack of an established trading market for the pre-funded warrants. TransCode has engaged ThinkEquity LLC as the exclusive placement agent for the offering, which is on a best-efforts basis with no minimum offering requirement. The proceeds are intended for product development activities, clinical trials, working capital, and other general corporate purposes. The offering is expected to close on or about July, 2024, subject to customary closing conditions.
TransCode Therapeutics, Inc. has announced the offering of common stock, pre-funded warrants to purchase common stock, and shares of common stock issuable upon the exercise of pre-funded warrants. The offering is detailed in a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. The prospectus supplement, dated July 22, 2024, outlines the terms of the offering, including the purchase price of shares and pre-funded warrants, the immediate exercisability of the pre-funded warrants, and the lack of an established trading market for the pre-funded warrants. TransCode has engaged ThinkEquity LLC as the exclusive placement agent for the offering, which is on a best-efforts basis with no minimum offering requirement. The proceeds are intended for product development activities, clinical trials, working capital, and other general corporate purposes. The offering is expected to close on or about July, 2024, subject to customary closing conditions.
TransCode Therapeutics, Inc.宣佈發行普通股、已預付款項的購買普通股權證和在行使預付款項的權利下可發行的普通股份。發行的詳細信息已在根據《證券法》第424(b)(5)條規定提交的招股說明書補充文件中說明。招股說明書補充文件於2024年7月22日發佈,概述了發行的條款,包括股份和預付款項的購買價格、預付款項的即時行使權以及預付款項的交易市場尚未建立。TransCode已委託ThinkEquity LLC作爲獨家包銷商,該計劃不設最低發行要求,僅基於最佳努力。所得款項擬用於產品開發活動、臨床試驗、營運資金和其他一般公司用途。該計劃預計將於2024年7月或前後結束,須符合慣例的收盤條件。
TransCode Therapeutics, Inc.宣佈發行普通股、已預付款項的購買普通股權證和在行使預付款項的權利下可發行的普通股份。發行的詳細信息已在根據《證券法》第424(b)(5)條規定提交的招股說明書補充文件中說明。招股說明書補充文件於2024年7月22日發佈,概述了發行的條款,包括股份和預付款項的購買價格、預付款項的即時行使權以及預付款項的交易市場尚未建立。TransCode已委託ThinkEquity LLC作爲獨家包銷商,該計劃不設最低發行要求,僅基於最佳努力。所得款項擬用於產品開發活動、臨床試驗、營運資金和其他一般公司用途。該計劃預計將於2024年7月或前後結束,須符合慣例的收盤條件。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。